Personalized versus evidence-based medicine with PET-based imaging (Q42941120)

11 November 2017

1 reference

title

Personalized versus evidence-based medicine with PET-based imaging (English)

1 reference

11 November 2017

evidence-based medicine

1 reference

Sandip Basu

1

1 reference

PubMed ID

20700107

11 November 2017

language of work or name

English

0 references

publication date

10 August 2010

1 reference

Nature Reviews Clinical Oncology

11 November 2017

1 reference

11 November 2017

7

1 reference

11 November 2017

11

1 reference

11 November 2017

665-668

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.121

11 November 2017

0 references

cites work

Feasibility of automated partial-volume correction of SUVs in current PET/CT scanners: can manufacturers provide integrated, ready-to-use software?

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

PET/CT for therapy response assessment in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

PET and PET/CT in gastrointestinal stromal tumours: the unanswered questions and the potential newer applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

FDG-PET in staging lung cancer: how does it change the algorithm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

FDG-PET and beyond: molecular breast cancer imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Survival after surgery for oesophageal cancer: a population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Recommendations on the use of 18F-FDG PET in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Ten years of rituximab in NHL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.121

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

31 March 2020

1 reference

12 December 2020

Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging

1 reference

12 December 2020

Unparalleled contribution of 18F-FDG PET to medicine over 3 decades.

1 reference

12 December 2020

PET imaging in neuroendocrine tumors: current status and future prospects.

1 reference

12 December 2020

Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1038/NRCLINONC.2010.121

Identifiers

DOI

1 reference

PubMed ID

20700107

Dimensions Publication ID

11 November 2017

0 references

1 reference

PubMed ID

20700107